Short answer
Niagen Bioscience, Inc. (NAGE) filed an 8-K current report with the SEC on March 19, 2026 reporting Item 8.01 (Other Events). Board increased share repurchase authorization to $20M from prior $10M, doubling buyback capacity to return capital to shareholders.
Niagen Bioscience, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Board increased share repurchase authorization to $20M from prior $10M, doubling buyback capacity to return capital to shareholders
- $2.6M of stock repurchased through March 17, 2026, showing initial program uptake and market activity
- Repurchases can occur via open market or private transactions, enhancing flexibility to optimize timing and pricing
- Program duration remains 24 months from original approval, with Board retaining discretion to suspend or modify
- Expanded buyback authorization signals confidence in stock valuation and commitment to shareholder returns
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Niagen Bioscience, Inc. 8-K filings
Get the next NAGE 8-K as it lands
Follow NAGE for push alerts, or ask the research agent what this filing means.